ENLIVEX LTD
ENLVNASDAQπ #5203 by market capUS Equity
$1.12βΌ $0.05 (β4.29%)
Market closed Β· at closeTrack ENLV
Get earnings, price moves & breaking news on Telegram
24hβΌ 4.3%
7dβΌ 11.5%
14dβΌ 12.9%
30dβΌ 60.1%
ytdβΌ 99.4%
1yβΌ 99.5%
π¦Market Cap
$2M
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
β
π΅FCF Margin
β
βοΈP/S Ratio
β
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $1.09 β $1.15
- 52-Week Range
- $1.00 β $434.40
- Volume (shares)
- 500
- Avg Volume (shares)
- β
- Shares Outstanding
- 1.5M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- 0.0
- P/S Ratio
- β
- EPS (TTM)
- $149.76
- Dividend Yield
- β
- Dilution (1yr)
- +120.1%
ENLIVEX LTD
ENLVFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$15MβΌ β3.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$10MβΌ β20.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
201Kβ² +120.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1MβΌ β$1M YoY
About ENLIVEX LTD
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst data unavailable.
Latest News & Updates
News unavailable.